Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a slow growing B-cell malignancy that remains incurable. Most patients with CLL relapse become refractory to treatment. Several newly approved agents have promising clinical activity in CLL, including "difficult-to-treat" populations. Educating oncology healthcare professionals about choosing between these new therapeutic options to treat patients with CLL will contribute to the effective management of this condition and could help improve patient outcomes.

Case 1: Relapsed CLL in a 71-Year-Old White Male With an 11q Deletion Who is Taking Anticoagulants to Manage Atrial Fibrillation

Case 2: Treatment of a 49-Year-Old White Male Presenting With Newly Diagnosed CLL Using the Principles of Shared Decision-Making

Case 3: Treatment of a 63-Year-Old White Male With CLL Using Emerging Targeted Therapies in the Relapsed/Refractory Setting

Learning Objectives

Evaluate patient and disease-related factors used to diagnose and risk-stratify patients with CLL in order to select appropriate treatment strategies; apply shared decision-making techniques when treating patients with CLL; define strategies to monitor and manage patients during "watch and wait" protocols and to identify disease progression

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)
Registration Opens: 
06/23/2015
Registration Expires: 
06/23/2017

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)

Accreditation Period

Registration Opens: 
06/23/2015
Registration Expires: 
06/23/2017
Please login or register to take this course.